Shanghai C and D INNOSTIC Medical Technology Group Co., Ltd. Class A

Shanghai C and D INNOSTIC Medical Technology Group Co., Ltd. Class A

SSZSE:301584
17.70
CNY
-0.47
(-2.59%)
0.89EPS
26.93P/E
7.84BMarket Cap

Total Valuation

CNY

As of September 30, 2026, Shanghai C and D INNOSTIC Medical Technology Group Co., Ltd. Class A carries a market capitalization of 7.84B, placing it among publicly traded companies globally. Its enterprise value stands at 10.12B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap7.84B
Enterprise Value10.12B

Share Statistics

As of September 30, 2026, Shanghai C and D INNOSTIC Medical Technology Group Co., Ltd. Class A has 423.29M shares outstanding.

Shares Outstanding423.29M

Valuation Ratios

As of September 30, 2026, Shanghai C and D INNOSTIC Medical Technology Group Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 26.93. The price-to-sales ratio is 0.40, and the price-to-book ratio stands at 3.50.

PE Ratio26.93
PS Ratio0.40
PB Ratio3.50
P/TBV Ratio3.56

Enterprise Valuation

As of September 30, 2026, Shanghai C and D INNOSTIC Medical Technology Group Co., Ltd. Class A trades at an EV/EBITDA multiple of 19.18 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.51 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 19.18 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 10.12B versus a market cap of 7.84B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales0.51
EV / EBITDA19.18
EV / EBIT19.18

Financial Position

As of September 30, 2026, Shanghai C and D INNOSTIC Medical Technology Group Co., Ltd. Class A maintains a current ratio of 1.15, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 143.10, indicating elevated leverage, while an interest coverage ratio of 5.51 demonstrates adequate ability to service its debt obligations.

Current Ratio1.15
Quick Ratio0.13
Debt / Equity143.10
Debt / EBITDA7.11
Interest Coverage5.51

Financial Efficiency

CNY

These figures cover the twelve months ended September 30, 2026. The company generates approximately 9.39M in revenue per employee across its workforce of 2,115.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee9.39M
Employee Count2,115.00

Taxes

CNY

Over the twelve months ended September 30, 2026, Shanghai C and D INNOSTIC Medical Technology Group Co., Ltd. Class A recorded 146.30M in income tax expense. That works out to an effective tax rate of 27.91, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 524.22M, leaving 292.55M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax146.30M
Effective Tax Rate27.91

Stock Price Statistics

CNY

As of the close on November 17, 2026, Shanghai C and D INNOSTIC Medical Technology Group Co., Ltd. Class A's stock has declined approximately 49.08% over the past 52 weeks. The 50-day moving average sits at 19.19, while the 200-day moving average is 23.71.

52-Week Price Change-49.08%
50-Day Moving Average19.19
200-Day Moving Average23.71

Income Statement

CNY

Over the twelve months ended September 30, 2026, Shanghai C and D INNOSTIC Medical Technology Group Co., Ltd. Class A generated 19.85B in revenue and converted that into 292.55M in net income, yielding earnings per share of 0.89. EBITDA reached 527.91M, while operating income came in at 734.22M.

Revenue19.85B
Gross Profit1.60B
Operating Income734.22M
Pretax Income524.22M
Net Income292.55M
EBITDA527.91M
EBIT527.91M
Earnings Per Share (EPS)0.89

Balance Sheet

CNY

As of September 30, 2026, Shanghai C and D INNOSTIC Medical Technology Group Co., Ltd. Class A holds 1.85B in cash and equivalents against 3.75B in total debt, resulting in a net debt position of 1.81B. Total book value stands at 2.24B, with working capital of 2.20B providing operational flexibility.

Cash & Cash Equivalents1.85B
Total Debt3.75B
Net Debt1.81B
Equity (Book Value)2.24B
Book Value Per Share5.30
Working Capital2.20B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-72.59M

Margins

Over the twelve months ended September 30, 2026, Shanghai C and D INNOSTIC Medical Technology Group Co., Ltd. Class A posted a gross margin of 8.04, reflecting its pricing power and cost economics. The operating margin of 3.70 and net profit margin of 1.47 provide insight into operational efficiency.

Gross Margin8.04
Operating Margin3.70
Pretax Margin2.64
Profit Margin1.47
EBITDA Margin2.66

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Shanghai C and D INNOSTIC Medical Technology Group Co., Ltd. Class A paid dividends of 0.52 per share. The dividend payout ratio of 47.39 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 13.57, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Shanghai C and D INNOSTIC Medical Technology Group Co., Ltd. Class A shareholders.

Dividend Per Share0.52
Payout Ratio47.39
Shareholder Yield13.57

Scores

As of September 30, 2026, Shanghai C and D INNOSTIC Medical Technology Group Co., Ltd. Class A has an Altman Z-Score of 1.92, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score1.92